Key result
Alcohol septal ablation in obstructive HCM shows 10-year survival comparable to non-obstructive HCM.
Why the study?
Data on procedural complications and long term survival after alcohol septal ablation in Chinese patients with obstructive hypertrophic cardiomyopathy were lacking.
Does alcohol septal ablation provide comparable long-term survival in patients with obstructive hypertrophic cardiomyopathy compared to patients with non-obstructive hypertrophic cardiomyopathy?
Cohort (n=530)
No
Does alcohol septal ablation provide comparable long-term survival in patients with obstructive hypertrophic cardiomyopathy compared to patients with non-obstructive hypertrophic cardiomyopathy?
Alcohol septal ablation for obstructive hypertrophic cardiomyopathy is associated with low periprocedural mortality and yields 10-year survival rates comparable to those of patients with non-obstructive hypertrophic cardiomyopathy.
Supports alcohol septal ablation for long-term survival in obstructive HCM; leaves open need for randomized confirmation.
Data on procedural complications and long term survival after alcohol septal ablation (ASA) in Chinese patients with obstructive hypertrophic cardiomyopathy (HOCM) are lacking. We aimed to investigate long-term survival of HOCM patients after ASA and compared to the non-obstructive hypertrophic cardiomyopathy(NOHCM). A total of 233 patients with HOCM and a peak pressure gradient of ≥50 mm Hg at rest or with provocation were consecutively enrolled from Fuwai Hospital in China between 2000 and 2012. Another 297 patients without left ventricular outflow tract obstruction were regarded as control group. Periprocedural mortality of ASA were low (0.89%). Periprocedural lethal ventricular arrhythmia occurred in 9 patients (4.0%). Alcohol volume (RR 1.44, 95% CI: 1.03-2.03, P = 0.034) and age ≤40 years old (RR 4.63, 95% CI: 1.07-20.0, P = 0.040) were independent predictors for periprocedural lethal ventricular arrhythmia. The 10- year overall survival was 94.6% in the ASA group, similar with 92.9% in the NOHCM group (P = 0.930). In conclusion, periprocedural mortality and complications were rare in ASA. Long term survival after ASA were satisfactory and comparable to NOHCM. Patients under 40 years old should be more cautious undergoing ASA, for these patients were more likely to endure lethal ventricular arrhythmia during periprocedural period of ASA.
No takes yet. Share an insight, caveat, or question.
An et al. (2017) conducted a cohort in Hypertrophic cardiomyopathy (n=530). Alcohol septal ablation vs. Non-obstructive hypertrophic cardiomyopathy was evaluated on 10-year overall survival (p=0.930). Alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy resulted in a 10-year overall survival of 94.6%, which was comparable to the 92.9% survival observed in patients with non-obstructive hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: